{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:06:54Z","timestamp":1785424014684,"version":"3.56.0"},"reference-count":20,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"College of Health and Human Sciences, Texas Tech University"},{"id":[{"id":"https:\/\/ror.org\/0405mnx93","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Primary liver cancer, particularly hepatocellular carcinoma (HCC), remains a major global health burden, ranking as the fifth most common cancer and the third leading cause of cancer-related mortality worldwide. The rising incidence of HCC is closely linked to metabolic comorbidities, including non-alcoholic fatty liver disease (NAFLD), underscoring the need for improved diagnostic and therapeutic strategies. NAFLD can progress to metabolic dysfunction-associated steatohepatitis (MASH), characterized by inflammation and fibrosis, which markedly increases HCC risk, especially in individuals with obesity and type 2 diabetes (T2D). NAFLD has recently been redefined as metabolic dysfunction-associated steatotic liver disease (MASLD) to better reflect its metabolic basis. However, robust experimental models to study the progression from MASLD to MASH and ultimately HCC remain limited. This proof-of-concept study investigates sex-specific effects of metabolic dysregulation using the STAM (STelic Animal Model; streptozotocin and high-fat diet) mouse model, which recapitulates key features of human MASH and HCC. Neonatal C57BL\/6J mice received streptozotocin to induce T2D-like symptoms followed by a high-fat diet. Streptozotocin (STZ) treated mice showed reduced body fat, lower insulin levels, impaired glucose tolerance, and increased expression of genes linked to inflammation, lipid metabolism, and apoptosis. These findings support the STAM model\u2019s utility for MASLD research and highlight the importance of sex-specific strategies to limit HCC progression.<\/jats:p>","DOI":"10.3390\/ijms27073200","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T08:08:34Z","timestamp":1775030914000},"page":"3200","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reproducibility and Sex Differences in a STZ\u2013High-Fat Diet Model of MASLD and Early Hepatocarcinogenesis"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4223-3366","authenticated-orcid":false,"given":"Marleigh","family":"Hefner","sequence":"first","affiliation":[{"name":"Obesity and Metabolic Health Laboratory, Department of Nutritional Sciences, Texas Tech University, Lubbock, TX 79409, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raksa Andalib","family":"Hia","sequence":"additional","affiliation":[{"name":"Obesity and Metabolic Health Laboratory, Department of Nutritional Sciences, Texas Tech University, Lubbock, TX 79409, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Obesity and Metabolic Health Laboratory, Department of Nutritional Sciences, Texas Tech University, Lubbock, TX 79409, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Nateqi","sequence":"additional","affiliation":[{"name":"Obesity and Metabolic Health Laboratory, Department of Nutritional Sciences, Texas Tech University, Lubbock, TX 79409, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil V.","family":"Dhurandhar","sequence":"additional","affiliation":[{"name":"Obesity and Metabolic Health Laboratory, Department of Nutritional Sciences, Texas Tech University, Lubbock, TX 79409, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4160-2764","authenticated-orcid":false,"given":"Vijay","family":"Hegde","sequence":"additional","affiliation":[{"name":"Obesity and Metabolic Health Laboratory, Department of Nutritional Sciences, Texas Tech University, Lubbock, TX 79409, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41575-022-00704-9","article-title":"Evolving therapeutic landscape of advanced hepatocellular carcinoma","volume":"20","author":"Yang","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s41571-023-00825-3","article-title":"Global trends in hepatocellular carcinoma epidemiology: Implications for screening, prevention and therapy","volume":"20","author":"Singal","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3350\/cmh.2022.0316","article-title":"Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990-2019: A DALY-based analysis of the Global Burden of Disease 2019 study","volume":"29","author":"Choi","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e70132","DOI":"10.1002\/edm2.70132","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Mechanisms, Clinical Implications and Therapeutic Advances","volume":"8","author":"Miller","year":"2025","journal-title":"Endocrinol. Diabetes Metab."},{"key":"ref_5","first-page":"884","article-title":"Non-alcoholic fatty liver disease, metabolic syndrome, and type 2 diabetes mellitus: Where do we stand today?","volume":"19","author":"Mitrovic","year":"2023","journal-title":"Arch. Med. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3389\/fonc.2020.00171","article-title":"Global Trends in Incidence Rates of Primary Adult Liver Cancers: A Systematic Review and Meta-Analysis","volume":"10","author":"Dasgupta","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_7","first-page":"54","article-title":"Progress and prospects of biomarkers in primary liver cancer (Review)","volume":"57","author":"Gao","year":"2020","journal-title":"Int. J. Oncol."},{"key":"ref_8","first-page":"53","article-title":"Sex differences in hepatocellular carcinoma","volume":"10","author":"Ho","year":"2024","journal-title":"Hepatoma Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1097\/HEP.0000000000000277","article-title":"Role of sex in liver tumor occurrence and clinical outcomes: A comprehensive review","volume":"79","author":"Toniutto","year":"2024","journal-title":"Hepatology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.molmed.2024.05.013","article-title":"Sexual dimorphism of metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Cherubini","year":"2024","journal-title":"Trends Mol. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cgh.2020.04.067","article-title":"Women have a lower risk of nonalcoholic fatty liver disease but a higher risk of progression vs men: A systematic review and meta-analysis","volume":"19","author":"Balakrishnan","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1084\/jem.20181288","article-title":"Adiponectin accounts for gender differences in hepatocellular carcinoma incidence","volume":"216","author":"Manieri","year":"2019","journal-title":"J. Exp. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1126\/science.1140485","article-title":"Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production","volume":"317","author":"Naugler","year":"2007","journal-title":"Science"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00795-013-0016-1","article-title":"A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma","volume":"46","author":"Fujii","year":"2013","journal-title":"Med. Mol. Morphol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.3748\/wjg.v18.i19.2300","article-title":"Animal models of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"18","author":"Takahashi","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.4254\/wjh.v7.i17.2110","article-title":"Recent advances in mouse models of obesity- and nonalcoholic steatohepatitis-associated hepatocarcinogenesis","volume":"7","author":"Nakagawa","year":"2015","journal-title":"World J. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.180605","article-title":"Streptozotocin-induced pancreatic insulitis: New model of diabetes mellitus","volume":"193","author":"Like","year":"1976","journal-title":"Science"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6506","DOI":"10.1038\/s41467-024-50660-y","article-title":"A male mouse model for metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma","volume":"15","author":"Jeong","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Liang, W., Menke, A.L., Driessen, A., Koek, G.H., Lindeman, J.H., Stoop, R., Havekes, L.M., Kleemann, R., and van den Hoek, A.M. (2014). Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0115922"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/7\/3200\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T07:58:43Z","timestamp":1775116723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/7\/3200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":20,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["ijms27073200"],"URL":"https:\/\/doi.org\/10.3390\/ijms27073200","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}